

L Number	Hits	Search Text	DB	Time stamp
-	974	((546/235) or (514/331)).CCLS.	USPAT; US-PGPUB	2004/08/23 17:04
-	1	(((546/235) or (514/331)).CCLS.) and (("5763458").PN.)	USPAT; US-PGPUB	2004/08/23 17:04
-	1	("5763458").PN.	USPAT; US-PGPUB	2004/08/24 11:01
-	0	("45930344800225").PN.	USPAT; US-PGPUB	2004/08/24 11:03
-	40	"4800225" "4593034"	USPAT; US-PGPUB	2004/08/24 11:03
-	2	((("4593034") or ("4800225"))).PN.	USPAT; US-PGPUB	2004/08/24 11:04

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in Cplus
NEWS 6 May 27 Cplus super roles and document types searchable in REGISTRY
NEWS 7 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)
NEWS 9 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction
with the 228th ACS National Meeting
NEWS 11 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 12 AUG 02 Cplus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 13 AUG 02 STN User Update to be held August 22 in conjunction with the
228th ACS National Meeting
NEWS 14 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 15 AUG 04 Pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover! will change September 1, 2004

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:42:23 ON 24 AUG 2004

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 10:42:44 ON 24 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Aug 2004 (20040824/PD)

FILE LAST UPDATED: 24 Aug 2004 (20040824/ED)

HIGHEST GRANTED PATENT NUMBER: US6782553

HIGHEST APPLICATION PUBLICATION NUMBER: US2004163153

CA INDEXING IS CURRENT THROUGH 24 Aug 2004 (20040824/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Aug 2004 (20040824/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2004

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2004

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (90182-92-6 OR 112885-41-3 OR 109872-41-5 OR 141196-99-8)/rn

45 90182-92-6/RN

9 112885-41-3/RN

2 109872-41-5/RN

2 141196-99-8/RN

L1 52 (90182-92-6 OR 112885-41-3 OR 109872-41-5 OR 141196-99-8)/RN

=> s l1 and asthma OR bronch?

24118 ASTHMA

30137 BRONCH?

L2 30137 L1 AND ASTHMA OR BRONCH?

=> s l1 and (asthma OR bronch?)

24118 ASTHMA

30137 BRONCH?

L3 11 L1 AND (ASTHMA OR BRONCH?)

=> d 1-11 cbib pi hitstr abs

L3 ANSWER 1 OF 11 USPATFULL on STN

2004:152312 Methods of treating and preventing narcolepsy using

enantiomerically pure (s)-didesmethylsibutramine.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Sepracor, Inc. (U.S. corporation)

US 2004116534 A1 20040617

APPLICATION: US 2003-717653 A1 20031121 (10)

PRIORITY: US 1998-99306P 19980902 (60)

US 1998-97665P 19980824 (60)

DOCUMENT TYPE: Utility; APPLICATION.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004116534 A1 20040617

IT 90182-92-6, Zacopride 90182-92-6D, Zacopride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 11 USPATFULL on STN

2004:121066 Methods of treating and preventing depression using didesmethylsibutramine.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Sepracor, Inc. (U.S. corporation)

US 2004092481 A1 20040513

APPLICATION: US 2003-693980 A1 20031028 (10)

PRIORITY: US 1998-99306P 19980902 (60)

US 1998-97665P 19980824 (60)

DOCUMENT TYPE: Utility; APPLICATION.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004092481 A1 20040513

IT 90182-92-6, Zacopride 90182-92-6D, Zacopride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 11 USPATFULL on STN

2004:88980 Methods of treating or preventing restless leg syndrome using sibutramine metabolites.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES

Fang, Qun K., Wellesley, MA, UNITED STATES

US 2004067957 A1 20040408

APPLICATION: US 2003-665448 A1 20030922 (10)

DOCUMENT TYPE: Utility; APPLICATION.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004067957 A1 20040408

IT 90182-92-6, Zacospride 90182-92-6D, Zacospride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 11 USPATFULL on STN

2003:277234 Methods of treating or preventing erectile dysfunction.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES

Fang, Qun K., Wellesley, MA, UNITED STATES

Sepracor Inc. (U.S. corporation)

US 2003195261 A1 20031016

APPLICATION: US 2003-395298 A1 20030325 (10)

PRIORITY: US 1998-97665P 19980824 (60)

US 1998-99306P 19980902 (60)

DOCUMENT TYPE: Utility; APPLICATION.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003195261 A1 20031016

IT 90182-92-6, Zacospride 90182-92-6D, Zacospride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT₃ antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 11 USPATFULL on STN

2003:140950 Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES

Fang, Qun K., Wellesley, MA, UNITED STATES

Sepracor, Inc. (U.S. corporation)

US 2003096792 A1 20030522

APPLICATION: US 2002-278097 A1 20021023 (10)

DOCUMENT TYPE: Utility; APPLICATION.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003096792 A1 20030522

IT 90182-92-6, Zacopride 90182-92-6D, Zacopride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 11 USPATFULL on STN

2002:330343 Methods of treating or preventing weight gain, obesity, and related disorders.

Jerussi, Thomas P., Framingham, MA, UNITED STATES

Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES

Fang, Qun K., Wellesley, MA, UNITED STATES

Sepracor Inc. (U.S. corporation)

US 2002188029 A1 20021212

APPLICATION: US 2001-806 A1 20011204 (10)

PRIORITY: US 1998-97665P 19980824 (60)

US 1998-99306P 19980902 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


PI US 2002188029 A1 20021212

US 6538034 B2 20030325

IT 90182-92-6, Zacospride 90182-92-6D, Zacospride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake

inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT.sub.3 antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 11 USPATFULL on STN

2002:323115 Compositions comprising dopamine reuptake inhibitors and methods of making and using the same.

Senanayake, Chrisantha Hugh, Shrewsbury, MA, UNITED STATES

Fang, Qun Kevin, Wellesley, MA, UNITED STATES

Han, Zhengxu, Shrewsbury, MA, UNITED STATES

Krishnamurthy, Dhileepkumar, Westboro, MA, UNITED STATES

Sepracor Inc. (U.S. corporation)

US 2002183281 A1 20021205

APPLICATION: US 2002-160033 A1 20020604 (10)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002183281 A1 20021205

US 6710087 B2 20040323


IT 90182-92-6, Zacopride 90182-92-6D, Zacopride,

stereoisomers, metabolites, and clathrates

(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 11 USPATFULL on STN

2002:308379 Medicament.

Skogvall, Staffan, Lund, SWEDEN

US 2002173505 A1 20021121

APPLICATION: US 2001-984329 A1 20011029 (9)

PRIORITY: SE 1999-1531 19990428

SE 1999-1906 19990526

SE 1999-2251 19990615

SE 1999-2252 19990615

WO 2000-SE819 20000428

US 1999-131355P 19990428 (60)

US 1999-136604P 19990527 (60)

US 1999-139632P 19990617 (60)

US 1999-139633P 19990617 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


PI US 2002173505 A1 20021121

IT 90182-92-6, Zacopride 109872-41-5, BRL 24924

112885-41-3, Mosapride 141196-99-8, SC-53116

(serotonergic agonists and antagonists for treatment of
bronchoconstriction-related disorders)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)

RN 109872-41-5 USPATFULL

CN Benzamide, 4-amino-N-(1R,4S,5R)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 112885-41-3 USPATFULL


CN Benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]- (9CI) (CA INDEX NAME)



RN 141196-99-8 USPATFULL

CN Benzamide, 4-amino-5-chloro-N-[[[(1S,7aS)-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A compound having agonist activity to the 5-HT.sub.4 receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving **bronchocontraction** of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Further, a compound having antagonist activity to the 5-HT.sub.2a receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment or disorders involving **bronchocontraction** of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Moreover, a composition comprising a combination of compounds comprising at least one compound with agonist activity to the 5-HT.sub.4 receptor agonist and at least one compound with antagonist activity to the 5-HT.sub.2, receptor antagonist is described, as well as such a composition for use as a medicament, the use of said composition for the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body, and methods of treatment, wherein said compositions are administered.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 11 USPATFULL on STN

2002:9889 Methods and compositions for the treatment and prevention of sexual dysfunction.

Jerussi, Thomas P., Framingham, MA, United States

Senanayake, Chrisantha H., Shrewsbury, MA, United States

Fang, Qun K., Wellesley, MA, United States

Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)

US 6339106 B1 20020115

APPLICATION: US 2000-662135 20000914 (9)

DOCUMENT TYPE: Utility; GRANTED.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6339106 B1 20020115

IT 90182-92-6, Zacospride 90182-92-6D, Zacospride,
stereoisomers, metabolites and clathrates
(sibutramine metabolite or other dopamine uptake inhibitors for
treatment and prevention of sexual dysfunction)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of sexual. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT.sub.3 antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 11 USPATFULL on STN

2001:231308 Methods of treating and preventing attention deficit disorders.

Jerussi, Thomas P., Framingham, MA, United States

Senanayake, Chrisantha H., Shrewsbury, MA, United States

Fang, Qun K., Wellesley, MA, United States

Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)

US 6331571 B1 20011218

APPLICATION: US 1999-372158 19990811 (9)

PRIORITY: US 1998-97665P 19980824 (60)

US 1998-99306P 19980902 (60)

DOCUMENT TYPE: Utility; GRANTED.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6331571 B1 20011218

IT 90182-92-6, Zacospride 90182-92-6D, Zacospride, stereoisomers, metabolites, and clathrates (dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)


RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



RN 90182-92-6 USPATFULL

CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI)
(CA INDEX NAME)



AB Methods are disclosed for the treatment and prevention of affective disorders with racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 11 USPATFULL on STN

2000:137861 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent.

Depui, Helene, Goteborg, Sweden

Hallgren, Agneta, Molndal, Sweden

AstraZeneca AB, Sodertalje, Sweden (non-U.S. corporation)

US 6132771 20001017

WO 9725065 19970717

APPLICATION: US 1997-750936 19970213 (8)

WO 1996-SE1736 19961220 19970213 PCT 371 date 19970213 PCT 102(e) date

PRIORITY: SE 1996-72 19960108

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6132771 20001017


WO 9725065 19970717

IT 112885-41-3, Mosapride

(oral pharmaceutical dosage forms comprising proton pump inhibitor and prokinetic agent for gastroesophageal reflux treatment)

RN 112885-41-3 USPATFULL

CN Benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)



AB An oral pharmaceutical dosage form comprising a proton pump inhibitor and one or more prokinetic agents in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of multilayered tablets, capsules or multiple unit tableted dosage forms. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with gastro oesophageal reflux diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (90182-92-6)/rn
L4 45 (90182-92-6)/RN

=> s 14 not 13
L5 35 L4 NOT L3

=> sort py
ENTER (L5), L#, OR L# RANGE:.
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L5
L6 35 SORT L5 PY

=> d 30-35 cbib pi

L6 ANSWER 30 OF 35 USPATFULL on STN
2002:67175 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation.
Wilson, Leland F., Menlo Park, CA, UNITED STATES
Doherty, Paul C., JR., Cupertino, CA, UNITED STATES
Place, Virgil A., Kawaihae, HI, UNITED STATES
Smith, William L., Montclair, NJ, UNITED STATES
Abdel-Hamid Abdou Ali, Ibrahim AbouBakr, Mansoura, EGYPT
US 2002037828 A1 20020328
APPLICATION: US 2001-888250 A1 20010621 (9)
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 2002037828 A1 20020328
US 6403597 B2 20020611

L6 ANSWER 31 OF 35 USPATFULL on STN
2002:19314 Bupropion metabolites and methods of use.
Jerussi, Thomas P., Framingham, MA, United States
McCullough, John R., Hudson, MA, United States
Senanayake, Chrisantha H., Shrewsbury, MA, United States
Fang, Qun K., Wellesley, MA, United States
Sepracor Inc., Marlborough, MA, United States (U.S. corporation)

US 6342496 B1 20020129

APPLICATION: US 2000-510241 20000222 (9)

PRIORITY: US 1999-122277P 19990301 (60)

US 1999-148324P 19990811 (60)

DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6342496 B1 20020129

L6 ANSWER 32 OF 35 USPATFULL on STN

2002:5997 Bupropion metabolites and methods of use.

Fang, Qun Kevin, Wellesley, MA, United States

Senanayake, Chrisantha Hugh, Shrewsbury, MA, United States

Grover, Paul, Franklin, MA, United States

Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)

US 6337328 B1 20020108

APPLICATION: US 2000-640725 20000818 (9)

PRIORITY: US 1999-148324P 19990811 (60)

US 1999-122277P 19990301 (60)

DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6337328 B1 20020108

L6 ANSWER 33 OF 35 USPATFULL on STN

2003:24165 Formulations of adenosine a1 agonists.

Bountra, Charanjit, Stevenage, UNITED KINGDOM

Clayton, Nicholas Maughan, Stevenage, UNITED KINGDOM

Naylor, Alan, Stevenage, UNITED KINGDOM

US 2003018008 A1 20030123

APPLICATION: US 2002-168190 A1 20020618 (10)

WO 2000-GB4902 20001219

PRIORITY: GB 1999-300774 19991220

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003018008 A1 20030123

L6 ANSWER 34 OF 35 USPATFULL on STN

2004:126445 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage.

Megens, Antonius Adrianus Hendrikus Petrus, Beerse, BELGIUM

US 2004096423 A1 20040520

APPLICATION: US 2003-432811 A1 20031224 (10)

WO 2001-EP13318 20011115

PRIORITY: EP 2000-204191 20001124

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004096423 A1 20040520

L6 ANSWER 35 OF 35 USPATFULL on STN

2004:121095 Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders.

Billstein, Stephan Anthony, Franklin Lakes, NJ, UNITED STATES

Dumovic, Peter, Mendham, NJ, UNITED STATES

Franco, Nicola, Sondersdorf, FRANCE

Iwicki, Mark Thomas, Long Valley, NJ, UNITED STATES

Pfannkuche, Hans-Jurgen, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF

Wilusz, Edward Joseph, JR., Pittstown, NJ, UNITED STATES

US 2004092511 A1 20040513

APPLICATION: US 2003-702688 A1 20031106 (10)

PRIORITY: US 1999-266333P 19991210 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004092511 A1 20040513

=> d 1-5 cbib pi

L6 ANSWER 1 OF 35 USPATFULL on STN

86:45139 Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes.

Welstead, Jr., William J., Richmond, VA, United States

A. H. Robins Company, Inc., Richmond, VA, United States (U.S. corporation)

US 4605652 19860812

APPLICATION: US 1985-697944 19850204 (6)

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4605652 19860812

L6 ANSWER 2 OF 35 USPATFULL on STN

86:32824 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides.

Munson, Jr., Harry R., Richmond, VA, United States

Boswell, Jr., Robert F., Richmond, VA, United States

A. H. Robins Company, Inc., Richmond, VA, United States (U.S. corporation)

US 4593034 19860603

APPLICATION: US 1984-597275 19840406 (6)

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4593034 19860603

L6 ANSWER 3 OF 35 USPATFULL on STN

87:26419 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function.

Imbert, Thierry F., Noisy Le Roi, France

Dorme, Nicole A. M., Paris, France

Langlois, Michel, Buc, France

Delalande S.A., Courbevoie, France (non-U.S. corporation)

US 4657911 19870414

APPLICATION: US 1983-509022 19830629 (6)

PRIORITY: FR 1982-11670 19820702

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4657911 19870414

L6 ANSWER 4 OF 35 USPATFULL on STN

88:6892 Method of using 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide-N-oxides to control emesis caused by anticancer drugs.

Teng, Lina C., Richmond, VA, United States

Bearekman, Stephen C., Richmond, VA, United States

Turnbull, Lennox B., Richmond, VA, United States

Alphin, Reevis S., Richmond, VA, United States

Smith, William L., Richmond, VA, United States

A. H. Robins Company, Incorporated, Richmond, VA, United States (U.S. corporation)

US 4722834 19880202

APPLICATION: US 1986-836521 19860305 (6)

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4722834 19880202

L6 ANSWER 5 OF 35 USPATFULL on STN

88:1117 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides

in a method for alleviating emesis caused by non-platinum anticancer drugs.

Alphin, Reeves S., Richmond, VA, United States

Smith, William L., Richmond, VA, United States

Munson, Jr., Harry R., Richmond, VA, United States

Boswell, Robert F., Richmond, VA, United States

A. H. Robins Company, Inc., Richmond, VA, United States (U.S. corporation)

US 4717563 19880105

APPLICATION: US 1986-836518 19860305 (6)

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4717563 19880105

=> s (109872-41-5 OR 141196-99-8)/rn

2 109872-41-5/RN

2 141196-99-8/RN

L7 3 (109872-41-5 OR 141196-99-8)/RN

=> d 1-3 cbib pi

L7 ANSWER 1 OF 3 USPATFULL on STN

2004:121095 Pharmaceutical combinations and their use in treating
gastrointestinal and abdominal viscera disorders.

Billstein, Stephan Anthony, Franklin Lakes, NJ, UNITED STATES

Dumovic, Peter, Mendham, NJ, UNITED STATES

Franco, Nicola, Sondersdorf, FRANCE

Iwicki, Mark Thomas, Long Valley, NJ, UNITED STATES

Pfannkuche, Hans-Jurgen, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF

Wilusz, Edward Joseph, JR., Pittstown, NJ, UNITED STATES

US 2004092511 A1 20040513

APPLICATION: US 2003-702688 A1 20031106 (10)

PRIORITY: US 1999-266333P 19991210 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2004092511 A1 20040513

L7 ANSWER 2 OF 3 USPATFULL on STN

2002:308379 Medicament.

Skogvall, Staffan, Lund, SWEDEN

US 2002173505 A1 20021121

APPLICATION: US 2001-984329 A1 20011029 (9)

PRIORITY: SE 1999-1531 19990428

SE 1999-1906 19990526

SE 1999-2251 19990615

SE 1999-2252 19990615

WO 2000-SE819 20000428

US 1999-131355P 19990428 (60)

US 1999-136604P 19990527 (60)

US 1999-139632P 19990617 (60)

US 1999-139633P 19990617 (60)

DOCUMENT TYPE: Utility; APPLICATION.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002173505 A1 20021121

L7 ANSWER 3 OF 3 USPATFULL on STN

89:6068 Pharmacologically active hydrated azabicyclo compound.

Smith, Paul, Harlow, England

Beecham Group, p.l.c., Brentford, England (non-U.S. corporation)

US 4800225 19890124

APPLICATION: US 1987-28256 19870320 (7)

10/009,559

Thomas McKenzie

PRIORITY: GB 1986-7163 19860322

DOCUMENT TYPE: Utility; Granted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4800225 19890124

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

STN INTERNATIONAL LOGOFF AT 10:53:30 ON 24 AUG 2004